KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials (2017 - 2020)

Amneal Pharmaceuticals has reported Raw Materials over the past 4 years, most recently at $162.7 million for Q1 2020.

  • Quarterly results put Raw Materials at $162.7 million for Q1 2020, changed N/A from a year ago — trailing twelve months through Mar 2020 was $162.7 million (changed N/A YoY), and the annual figure for FY2019 was $172.2 million, down 5.23%.
  • Raw Materials for Q1 2020 was $162.7 million at Amneal Pharmaceuticals, down from $172.2 million in the prior quarter.
  • Over the last five years, Raw Materials for AMRX hit a ceiling of $205.1 million in Q3 2018 and a floor of $140.1 million in Q4 2017.
  • Median Raw Materials over the past 4 years was $180.9 million (2018), compared with a mean of $178.4 million.
  • Biggest five-year swings in Raw Materials: grew 29.71% in 2018 and later dropped 11.13% in 2019.
  • Amneal Pharmaceuticals' Raw Materials stood at $140.1 million in 2017, then grew by 29.71% to $181.7 million in 2018, then decreased by 5.23% to $172.2 million in 2019, then dropped by 5.48% to $162.7 million in 2020.
  • The last three reported values for Raw Materials were $162.7 million (Q1 2020), $172.2 million (Q4 2019), and $182.8 million (Q3 2019) per Business Quant data.